Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

India established Comprehensive Lactation Management Centres for feeding low birth weight babies in ICUs

Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role

Sun Pharma’s Utreglutide demonstrates significant weight loss at the American Diabetes Association 84th Scientific Sessions

GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024

Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis

New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Ginkgo Bioworks and Novo Nordisk to collaborate across R&D value chain

The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus